Table 1 Clinical data of the patients analysed in this study

From: Increased expression of the Th17-IL-6R/pSTAT3/BATF/RorγT-axis in the tumoural region of adenocarcinoma as compared to squamous cell carcinoma of the lung

Patient Number

Sample-ID

Histological Classification

Grading

T

N

M

Gender

Age

1

P2

ADC

G3

3

0

0

Male

69

2

P4

ADC

G3

3

0

0

Male

63

3

P5

ADC

G3

2b

0

0

Male

71

4

P6

ADC

G3

2

2

#

Female

64

5

P7

ADC

G3

3

0

0

Male

68

6

P12

ADC

G3

2b

1

0

Male

70

7

P14

ADC

G1

4

0

1

Male

75

8

P20

ADC

G3

2

0

0

Male

64

9

P22

ADC

G3

2a

1

0

Male

69

10

P26

ADC

G3

3

0

0

Male

48

11

P27

ADC

G2

1

0

0

Female

63

12

P28

ADC

G2

1b

0

0

Female

38

13

P31

ADC

G2

1b

2

0

Female

70

14

P33

ADC

G2

2b

2

0

Male

57

15

P37

ADC

G3

2a

0

0

Male

51

16

P38

ADC

G3

1a

0

0

Female

37

17

3-MP-IL35

ADC

G3

2a

0

0

Male

79

18

9-MP-IL35

ADC

G2

1b

2

0

Female

84

19

15-MP-IL35

ADC

G3

1b

0

0

Male

63

20

16-MP-IL35

ADC

G3

3

0

0

Female

70

21

17-MP-IL35

ADC

G2

2

0

0

Male

74

22

19-MP-IL35

ADC

#

2b

0

0

Female

55

23

22-MP-IL35

ADC

G3

2b

1

0

Male

68

24

23-MP-IL35

ADC

G2

2a

0

0

Male

73

25

26-MP-IL35

ADC

G3

1a

0

1

Female

52

26

27-MP-IL35

ADC

G3

1a

0

0

Female

70

27

28-MP-IL35

ADC

G3

1a

0

0

Male

76

28

32-MP-IL35

ADC

G3

2a

2

0

Female

60

29

34-MP-IL35

ADC

G3

1

0

0

Female

51

30

35-MP-IL35

ADC

G3

1b

0

0

Female

72

31

P1

SCC

G3

2

0

0

Female

66

32

P11

SCC

G3

2

0

0

Female

68

33

P15

SCC

G2

1b

0

0

Male

67

34

P18

SCC

G3

2a

0

0

Male

70

35

P19

SCC

G2

4

1

0

Male

48

36

P24

SCC

G2

2a

1

0

Male

61

37

P25

SCC

G3

2b

0

0

Male

72

38

P29

SCC

G2

2a

0

0

Female

69

39

P35

SCC

G2

1a

0

0

Male

45

40

1-MP-IL35

SCC

G3

1b

0

0

Male

80

41

2-MP-IL35

SCC

G3

1a

0

0

Male

57

42

4-MP-IL35

SCC

G3

1b

1

0

Female

53

43

5-MP-IL35

SCC

G2

3

0

0

Female

67

44

8-MP-IL35

SCC

G3

3

0

0

Male

66

45

13-MP-IL35

SCC

G3

1b

0

0

Male

69

46

14-MP-IL35

SCC

G2

1a

0

0

Female

58

47

21-MP-IL35

SCC

G1

1b

0

0

Male

41

48

29-MP-IL35

SCC

G3

1b

0

0

Male

74

49

30-MP-IL35

SCC

G3

1a

0

0

Female

70

50

36-MP-IL35

SCC

G3

2a

1

0

Male

74

  1. T-extent of primary tumor: 0: No evidence of primary tumor; 1a: Tumor 2 cm or less in greatest dimension; 1b: Tumor more than 2 cm but not more than 3 cm in greatest dimension; 2a: Tumor more than 3 cm but not more than 5 cm in greatest dimension; 2b: Tumor more than 5 cm but not more than 7 cm in greatest dimension; 3: Tumor more than 7 cm; 4: Tumor of any size that invades the mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, or with separate tumor nodules in a different ipsilateral lobe.
  2. N-regional lymph node metastasis: 0: No regional lymph node metastasis; 1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension; 2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s).
  3. M-peripheral metastasis: 0: No distant metastasis; 1: Distant metastasis.
  4. Histopathological grading: G1: well differentiated; G2: moderately differentiated; G3: Poorly differentiated.
  5. # No information available.